Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 67% Improvement Relative Risk ICU admission 86% Hospitalization time 26% c19early.org/k Saviano et al. Probiotics for COVID-19 RCT LATE TREATMENT Is late treatment with probiotics beneficial for COVID-19? RCT 80 patients in Italy Lower ICU admission (p=0.24) and shorter hospitalization (p=0.52), not stat. sig. Saviano et al., J. Clinical Medicine, doi:10.3390/jcm11133758 Favors probiotics Favors control
COVID-19 Pneumonia and Gut Inflammation: The Role of a Mix of Three Probiotic Strains in Reducing Inflammatory Markers and Need for Oxygen Support
Saviano et al., Journal of Clinical Medicine, doi:10.3390/jcm11133758
Saviano et al., COVID-19 Pneumonia and Gut Inflammation: The Role of a Mix of Three Probiotic Strains in Reducing Inflammatory.., Journal of Clinical Medicine, doi:10.3390/jcm11133758
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 80 COVID-19 interstitial pneumonia patients in Italy, 40 treated with probiotics, showing significantly reduced gut inflammatory markers with treatment, and lower ICU admission and mortality, without statistical significance. Bifidobacterium lactis LA 304, lactobacillus salivarius LA 302, and lactobacillus acidophilus LA 201 bid for 10 days.
The immune effects of probiotics are strain-specific.
Although the 67% lower mortality is not statistically significant, it is consistent with the significant 61% lower mortality [37‑76%] from meta analysis of the 8 mortality results to date.
risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 40 (0.0%), control 1 of 40 (2.5%), NNT 40, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 40 (0.0%), control 3 of 40 (7.5%), NNT 13, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
hospitalization time, 26.3% lower, relative time 0.74, p = 0.52, treatment mean 14.0 (±6.0) n=40, control mean 19.0 (±10.0) n=40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Saviano et al., 28 Jun 2022, Randomized Controlled Trial, Italy, peer-reviewed, mean age 59.8, 9 authors.
Contact: veronica.ojetti@policlinicogemelli.it (corresponding author), angela.saviano@policlinicogemelli.it, alessio.migneco@policlinicogemelli.it, flavia.nasella@gmail.com, francesco.franceschi@policlinicogemelli.it, annalisa.potenza@policlinicogemelli.it, claudia.tarli@policlinicogemelli.it, valentina.siciliano@policlinicogemelli.it, carminepetruzziello@live.it.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Abstract: Journal of Clinical Medicine Article COVID-19 Pneumonia and Gut Inflammation: The Role of a Mix of Three Probiotic Strains in Reducing Inflammatory Markers and Need for Oxygen Support Angela Saviano 1 , Annalisa Potenza 2 , Valentina Siciliano 3 , Carmine Petruzziello 4 , Claudia Tarli 2 , Alessio Migneco 1 , Flavia Nasella 1 , Francesco Franceschi 1 and Veronica Ojetti 1, * 1 2 3 4 * Citation: Saviano, A.; Potenza, A.; Siciliano, V.; Petruzziello, C.; Tarli, C.; Migneco, A.; Nasella, F.; Franceschi, F.; Ojetti, V. COVID-19 Pneumonia and Gut Inflammation: The Role of a Mix of Three Probiotic Strains in Reducing Inflammatory Markers and Need for Oxygen Support. J. Clin. Med. 2022, 11, 3758. https://doi.org/ 10.3390/jcm11133758 Academic Editors: Uri Kopylov and Andrew Day Received: 14 May 2022 Accepted: 26 June 2022 Published: 28 June 2022 Publisher’s Note: MDPI stays neutral Emergency Medicine Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00165 Rome, Italy; angela.saviano@policlinicogemelli.it (A.S.); alessio.migneco@policlinicogemelli.it (A.M.); flavia.nasella@gmail.com (F.N.); francesco.franceschi@policlinicogemelli.it (F.F.) Internal Medicine Department, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00165 Rome, Italy; annalisa.potenza@policlinicogemelli.it (A.P.); claudia.tarli@policlinicogemelli.it (C.T.) Department of Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00165 Rome, Italy; valentina.siciliano@policlinicogemelli.it Emergency Medicine Department, Ospedale San Carlo di Nancy, 00165 Rome, Italy; carminepetruzziello@live.it Correspondence: veronica.ojetti@policlinicogemelli.it Abstract: Background: COVID-19 disease, which typically presents with respiratory symptoms, can trigger intestinal inflammation through SARS-CoV-2 replication in the gastrointestinal tract. Supplementation with probiotics may have beneficial effects on gut inflammation due to their analgesic and anti-inflammatory properties. The primary objective of our study was to evaluate the efficacy of a mix of three probiotic strains (Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302, and Lactobacillus acidophilus LA 201; Lactibiane Iki® ) in the reduction in fecal calprotectin in patients with COVID-19 pneumonia, compared to a control group. The secondary aim was to evaluate the reduction in oxygen support and length of hospital stay in patients taking the probiotic mix. Patients and Methods: We conducted a prospective randomized controlled trial at Fondazione Policlinico Gemelli, Rome. We enrolled patients with COVID-19 interstitial pneumonia. One group received the probiotic mix twice a day for 10 days in addition to the standard COVID-19 therapy, and a second group received standard COVID-19 therapy without probiotics. We administered oxygen support (through Ventimask or Optiflow® ) on days (D) 1, 3, 5, 7 and 10, and the level of fecal calprotectin between D3–D5 and D7–D10. Results: A total of 80 patients (44 M/36 F; mean age: 59.8 ± 17.3) were enrolled with a mean value of calprotectin at enrollment of 140 mg/dL. At D7–10, the probiotic group showed a 35% decrease in fecal calprotectin compared to 16% in the control group, a decrease in C-reactive protein (CRP) of 72.7% compared to 62%, and a slight but not significant decrease in oxygen support compared to the control group. Conclusion: Supplementation with a mix of probiotics for 10 days in patients with COVID-19 interstitial..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit